Drugs / NTB-928
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07690189 | Jun 2026 → Jun 2028 expected | — | TeneoSeven, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTB-928 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07690189 ↗ |
| Modality | Protein / enzyme biologic | “NTB-928, a FRα-Targeting Bispecific T Cell Engager” NCT07690189 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT07690189 ↗ |